Impax Laboratories Inc. (IPXL)

17.90
0.22 1.24
NYSE : Health Technology
Prev Close 17.68
Open 17.72
Day Low/High 17.50 / 18.29
52 Wk Low/High 13.47 / 18.29
Volume 839.29K
Avg Volume 916.90K
Exchange NYSE
Shares Outstanding 73.87M
Market Cap 1.35B
EPS -6.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Interesting IPXL Put And Call Options For December 21st

Investors in Impax Laboratories Inc saw new options begin trading this week, for the December 21st expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Novartis May Sell U.S. Generic Pill Business Amid Industry Struggles

Novartis May Sell U.S. Generic Pill Business Amid Industry Struggles

The Swiss pharmaceutical firm's U.S. generic pill business could attract as much as $1.6 billion, Reuters reported.

Impax Laboratories Reaches Analyst Target Price

Impax Laboratories Reaches Analyst Target Price

In recent trading, shares of Impax Laboratories Inc have crossed above the average analyst 12-month target price of $20.00, changing hands for $20.40/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Impax Laboratories, Inc. And Encourages Shareholders To Contact The Firm For Additional Information

INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Impax Laboratories, Inc. And Encourages Shareholders To Contact The Firm For Additional Information

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Impax...

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Impax Laboratories, Inc. And Encourages Investors To Contact The Firm For Additional Information

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Impax Laboratories, Inc. And Encourages Investors To Contact The Firm For Additional Information

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Impax...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors Of An Investigation Concerning Whether The Sale Of Impax Laboratories, Inc. To Amneal Pharmaceuticals LLC Is Fair To Shareholders

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors Of An Investigation Concerning Whether The Sale Of Impax Laboratories, Inc. To Amneal Pharmaceuticals LLC Is Fair To Shareholders

The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Impax Laboratories, Inc.

Short Interest Drops 16% For IPXL

Short Interest Drops 16% For IPXL

The most recent short interest data has been released for the 09/29/2017 settlement date, which shows a 1,267,098 share decrease in total short interest for Impax Laboratories Inc , to 6,715,215, a decrease of 15.87% since 09/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Impax Shares Jump on Merger Buzz

Impax Shares Jump on Merger Buzz

Impax's shares soar after the Wall Street Journal reported that the drug maker is in merger discussions with Amneal Pharmaceuticals.

Impax Shares Jump After Chinese Firm Reveals 5% Stake

Impax Shares Jump After Chinese Firm Reveals 5% Stake

Shanghai Fosun Pharmaceutical owns 3.85 million shares, according to a 13G filing.

Teva, Mylan Seen to Stay on M&A Sidelines

Teva, Mylan Seen to Stay on M&A Sidelines

Teva is 'in no shape' to be making acquisitions while Mylan is 'still pretty leveraged,' says Oppenheimer analyst Derek Archila.

Teva's Massive Debt Load Just Became an Even Bigger Issue

Teva's Massive Debt Load Just Became an Even Bigger Issue

It is just not going to get better anytime soon.

Teva Shares Are Getting Obliterated Again After Vicious Investment Bank Downgrades

Teva Shares Are Getting Obliterated Again After Vicious Investment Bank Downgrades

Teva's stock is crumbling as another analyst slams it with a downgrade.

Teva Shares Are Taking a Beating and Dragging Down the Generic Drugmakers

Teva Shares Are Taking a Beating and Dragging Down the Generic Drugmakers

Teva said weak U.S. markets and the ongoing political turmoil in Venezuela weighed on the company's second quarter performance.

Biotech Movers: Impax Shares Jump on FDA Approval for Generic Version of Concerta

Biotech Movers: Impax Shares Jump on FDA Approval for Generic Version of Concerta

Impax Laboratories, Akebia Therapeutics and Alder BioPharmaceuticals were among the biotech movers in premarket trading on July 17.

Biotech Movers: Immuno-Oncology Pact With Celgene Sends BeiGene Shares Soaring

Biotech Movers: Immuno-Oncology Pact With Celgene Sends BeiGene Shares Soaring

BeiGene and Impax Laboratories were among the biotech movers in premarket trading on July 6.

Biotech Movers: Adamis Shares Jump After FDA Approves Epinephrine Pre-filled Syringe

Biotech Movers: Adamis Shares Jump After FDA Approves Epinephrine Pre-filled Syringe

Adamis Pharmaceuticals, Impax Laboratories and Accorda Therapeutics were among the biotech stock movers in premarket trading on June 16.

TheStreet Quant Rating: D (Sell)